Trial Profile
Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Bayer
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 20 Nov 2017 Planned patient number changed from 3000 to 31336.
- 20 Nov 2017 Status changed from active, no longer recruiting to completed.